Reassessment of the cefaclor breakpoint for Streptococcus pneumoniae

Fiona MacKenzie, K. E. Milne, Ian M Gould

    Research output: Contribution to journalArticle

    3 Citations (Scopus)

    Abstract

    Discrepancies between proven clinical success of cefaclor and its relatively poor activity in vitro were investigated against eight pneumococcal isolates. The bacteriostatic minimum inhibitory concentration (MIC) (the concentration resulting in no growth/kill relative to the starting inoculum) was derived from time kill studies. Bioassay results demonstrated an in vitro half-life of >24 and 9 h for cefuroxime and cefaclor, respectively. The mean NCCLS MIC for cefaclor was 1.4 and 0.3 mg/l for cefuroxime. The corresponding mean bacteriostatic MICs were 0.24 and 0.16 mg/l. Whilst cefaclor NCCLS MICs were significantly higher compared with cefuroxime MICs (P = 0.00058) there was no statistical differences between the bacteriostatic MICs (P = 0.259). Bacteriostatic MIC determination established that cefaclor and cefuroxime are equally active against pneumococci. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

    Original languageEnglish
    Pages (from-to)337-342
    Number of pages5
    JournalInternational Journal of Antimicrobial Agents
    Volume23
    Issue number4
    DOIs
    Publication statusPublished - 2004

    Keywords

    • S. pneumoniae
    • cefaclor
    • MICs
    • OTITIS-MEDIA
    • SUSCEPTIBILITY

    Cite this

    Reassessment of the cefaclor breakpoint for Streptococcus pneumoniae. / MacKenzie, Fiona; Milne, K. E.; Gould, Ian M.

    In: International Journal of Antimicrobial Agents, Vol. 23, No. 4, 2004, p. 337-342.

    Research output: Contribution to journalArticle

    @article{dc3c90ada5cc4698accc6b04fbb8b5d7,
    title = "Reassessment of the cefaclor breakpoint for Streptococcus pneumoniae",
    abstract = "Discrepancies between proven clinical success of cefaclor and its relatively poor activity in vitro were investigated against eight pneumococcal isolates. The bacteriostatic minimum inhibitory concentration (MIC) (the concentration resulting in no growth/kill relative to the starting inoculum) was derived from time kill studies. Bioassay results demonstrated an in vitro half-life of >24 and 9 h for cefuroxime and cefaclor, respectively. The mean NCCLS MIC for cefaclor was 1.4 and 0.3 mg/l for cefuroxime. The corresponding mean bacteriostatic MICs were 0.24 and 0.16 mg/l. Whilst cefaclor NCCLS MICs were significantly higher compared with cefuroxime MICs (P = 0.00058) there was no statistical differences between the bacteriostatic MICs (P = 0.259). Bacteriostatic MIC determination established that cefaclor and cefuroxime are equally active against pneumococci. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.",
    keywords = "S. pneumoniae, cefaclor, MICs, OTITIS-MEDIA, SUSCEPTIBILITY",
    author = "Fiona MacKenzie and Milne, {K. E.} and Gould, {Ian M}",
    year = "2004",
    doi = "10.1016/j.ijantimicag.2003.09.019",
    language = "English",
    volume = "23",
    pages = "337--342",
    journal = "International Journal of Antimicrobial Agents",
    issn = "0924-8579",
    publisher = "Elsevier Science B. V.",
    number = "4",

    }

    TY - JOUR

    T1 - Reassessment of the cefaclor breakpoint for Streptococcus pneumoniae

    AU - MacKenzie, Fiona

    AU - Milne, K. E.

    AU - Gould, Ian M

    PY - 2004

    Y1 - 2004

    N2 - Discrepancies between proven clinical success of cefaclor and its relatively poor activity in vitro were investigated against eight pneumococcal isolates. The bacteriostatic minimum inhibitory concentration (MIC) (the concentration resulting in no growth/kill relative to the starting inoculum) was derived from time kill studies. Bioassay results demonstrated an in vitro half-life of >24 and 9 h for cefuroxime and cefaclor, respectively. The mean NCCLS MIC for cefaclor was 1.4 and 0.3 mg/l for cefuroxime. The corresponding mean bacteriostatic MICs were 0.24 and 0.16 mg/l. Whilst cefaclor NCCLS MICs were significantly higher compared with cefuroxime MICs (P = 0.00058) there was no statistical differences between the bacteriostatic MICs (P = 0.259). Bacteriostatic MIC determination established that cefaclor and cefuroxime are equally active against pneumococci. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

    AB - Discrepancies between proven clinical success of cefaclor and its relatively poor activity in vitro were investigated against eight pneumococcal isolates. The bacteriostatic minimum inhibitory concentration (MIC) (the concentration resulting in no growth/kill relative to the starting inoculum) was derived from time kill studies. Bioassay results demonstrated an in vitro half-life of >24 and 9 h for cefuroxime and cefaclor, respectively. The mean NCCLS MIC for cefaclor was 1.4 and 0.3 mg/l for cefuroxime. The corresponding mean bacteriostatic MICs were 0.24 and 0.16 mg/l. Whilst cefaclor NCCLS MICs were significantly higher compared with cefuroxime MICs (P = 0.00058) there was no statistical differences between the bacteriostatic MICs (P = 0.259). Bacteriostatic MIC determination established that cefaclor and cefuroxime are equally active against pneumococci. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

    KW - S. pneumoniae

    KW - cefaclor

    KW - MICs

    KW - OTITIS-MEDIA

    KW - SUSCEPTIBILITY

    U2 - 10.1016/j.ijantimicag.2003.09.019

    DO - 10.1016/j.ijantimicag.2003.09.019

    M3 - Article

    VL - 23

    SP - 337

    EP - 342

    JO - International Journal of Antimicrobial Agents

    JF - International Journal of Antimicrobial Agents

    SN - 0924-8579

    IS - 4

    ER -